Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
5 participants
INTERVENTIONAL
2010-12-31
2028-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Apotransferrin in Patients With β-thalassemia
NCT03993613
Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid
NCT00437450
Pharmacokinetics of Afamelanotide in EPP Patients
NCT06388642
Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia
NCT00954486
Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia
NCT05660785
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
human apotransferrin
intravenous apotransferrin every 4-8 weeks
Human apotransferrin
intravenous infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Human apotransferrin
intravenous infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent
Exclusion Criteria
* Having detectable anti-immunoglobulin A antibodies
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Prothya Biosolutions
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cristina R Diaz de Heredia Rubio, PhD, MD
Role: PRINCIPAL_INVESTIGATOR
Vall d'Hebron, Spain
Katja Moser, MD
Role: PRINCIPAL_INVESTIGATOR
klinikum Aschaffenburg, Germany
Raffaella Mariani, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
AO San Gerardo Monza, Italy
Alberto Piperno, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
AO San Gerardo Monza, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinikum Aschaffenburg
Aschaffenburg, , Germany
AO San Gerardo
Monza, , Italy
Vall d'Hebron Hospital
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MD2009.04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.